Trimetazidine prevents cochlear lesions induced by intraperitoneal and perilymphatic administration of kainic acid

Brain Research

Volumn 826, Issue 1, 1999, Pages 95-103

  Gil Loyzaga, Pablo ^a   Hernández, Esther ^a   Carricondo, Francisco ^a   Simón, Fernando ^a   Poch Broto, Joaquín ^a  

^a Fac Med Ctr Cell Culture CAI U   (Spain)

Author keywords

Cochlea; Electrophysiology; Kainic acid; Neurotoxicity; Trimetazidine

Indexed keywords

KAINIC ACID; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HYPOXIA; BRAIN ISCHEMIA; CELL SWELLING; COCHLEA INJURY; COCHLEAR NERVE; CONTROLLED STUDY; CORTI ORGAN; DENDRITE; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT PERIOD; MALE; NERVE POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PERILYMPH; PRIORITY JOURNAL; RAT; SENSORY NERVE;

ANIMALS; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID AGONISTS; INJECTIONS, INTRALYMPHATIC; INJECTIONS, INTRAPERITONEAL; KAINIC ACID; MALE; MICROSCOPY, ELECTRON; NERVE DEGENERATION; NEUROTOXINS; ORGAN OF CORTI; RATS; RATS, LONG-EVANS; REACTION TIME; TRIMETAZIDINE; VASODILATOR AGENTS; VESTIBULOCOCHLEAR NERVE;

EID: 0344780751     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01258-5     Document Type: Article

References (60)

1. Aubert A., Bernard C., Clauser P., Harpey C., Vaudry H. A cellular anti-ischemic agent trimetazidine prevents the deleterious effects of oxygen free-radicals on the internal ear. Ann. Otolaryngol. Chir. Cervicofac. 107:1990;28-35.
2. Aubert A., Christian B., Pascale C., Harpey C., Vaudry H. Effect of phenazine methosulfate on electrophysiological activity of the semicircular canal: antioxidant properties of trimetazidine. Eur. J. Pharmacol. 174:1989;215-225.
3. Berg M., Bruhn T., Frandsen A.A., Schousboe A., Diemer N.H. Kainic acid induced seizures and brain damage in the rat: role of calcium homeostasis. J. Neurosci. Res. 40:1995;641-646.
4. Bledsoe S.C. Jr., Bobbin R.P., Chihal D.M. Kainic acid: an evaluation of its action on cochlear potentials. Hear. Res. 4:1981;109-120.
5. Boucher F.R., Hearse D.J., Opie L.H. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J. Cardiovasc. Pharmacol. 24:1994;45-49.
6. Choi D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11:1988;465-469.
7. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:1990;171-182.
8. Coyas A. The efficacy of trimetazidine in cochleovestibular disorders of ischemic origin. A crossover control versus placebo trial. Ann. Otolaryngol. Chir. Cervicofac. 107:1990;82-87.
9. Creagh T., Lanigan D., Dolan J., Tormey W., Walshe J.J., Bouchier-Hayes D. Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine. J. Urol. 149:1993;915-917.
10. Davies K.J.A., Goldberg A.L. Proteins damaged by oxygen radicals are rapidly degraded in extracts of red blood cells. J. Biol. Chem. 262:1987;8227-8234.
11. Davies K.J.A., Lin S.W., Pacifici R.E. Protein damage and degradation by oxygen radicals: IV. Degradation of denaturated protein. J. Biol. Chem. 262:1987;9914-9920.
12. Eybalin M. Neurotransmitters and neuromodulators of the mammalian cochlea. Physiol. Rev. 73:1993;309-373.
13. Fantini E., Athias P., Demaison L., Grynberg A. Protective effects of trimetazidine on hypoxic cardiac myocytes from the rat. Fundam. Clin. Pharmacol. 11:1997;427-439.
14. Fantini E., Demaison L., Sentex E., Grynberg A., Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J. Mol. Cell. Cardiol. 26:1994;949-958.
15. Fechter L.D., Liu Y., Pearce T.A. Cochlear protection from carbon monoxide exposure by free radical blockers in the guinea pig. Toxicol. Appl. Pharmacol. 142:1997;47-55.
16. Gil-Loyzaga P., Pujol R. Neurotoxicity of kainic acid in the rat cochlea during early developmental stages. Eur. Arch. Oto-Rhino-Laryngol. 248:1990;40-48.
17. P. Gil-Loyzaga, R. Pujol, Kainic acid toxicity on cochlear type I neurons, in: T. Sacristán, J.J. Alvarez-Vicent, F. Antolí-Candela, L. Rubio (Eds.), Otorhinolaryngology Head and Neck Surgery, Kugler and Ghedini Publications, Amsterdam, 1990, pp. 37-39.
18. Gil-Loyzaga P., Hernandez-Ortíz M.J., Rodriguez-Benito T., Lasso de la Vega M. Diltiazem protects against neurotoxicity induced by excitotoxic aminoacids on cochlear afferent fibers. A morphological study. ORL. 55:1993;211-215.
19. Haguenauer J.P. Trimetazidine in degenerative hypoacusis: effects on hearing and integration. Drugs Today. 26:1990;59-65. Suppl. 13.
20. Janssen R. Glutamate neurotoxicity in the developing rat cochlea is antagonized by kynurenic acid and MK-801. Brain Res. 590:1992;201-206.
21. R. Janssen, K.F. Jensen, Glutamate excitotoxicity in rat inner ear, 11th Assoc. Res. Otolaryngol. Midwinter Meet., FL, USA, 1988.
22. Janssen R., Schweitzer L., Jensen K.F. Glutamate neurotoxicity in the developing rat cochlea: physiological and morphological approaches. Brain Res. 552:1991;255-264.
23. Juiz J.M., Rueda J., Merchán J.A., Sala M.L. The effects of kainic acid on the cochlear ganglion of the rat. Hear. Res. 40:1989;65-74.
24. Klyskens P., Lambert P., D'Hooge D. Trimetazidine contre bétahistine dans la maladie de Meniere. Etude à double iusu. Ann. Otolaryngol. (Paris). 107:1990;11-19.
25. Konishi T. Action of tubocurarine and atropine on the crossed olivocochlear bundle. Acta Otolaryngol. 74:1972;252-264.
26. Kontos H.A. Oxygen radicals in cerebral vascular injury. Circ. Res. 57:1985;508-516.
27. Kusakari J., Arakawa E., Rokugo M., Ohyama K., Inamura N. Effect of kainic acid upon N1 latency. Laryngoscope. 94:1984;1365-1369.
28. Labrid C. Cellular disorders induced by ischaemia: the action of trimetazidine. Presse Med. 15:1986;1754-1757.
29. i regulation in the rat isolated ventricular myocyte. Br. J. Pharmacol. 117:1996;831-838.
30. 31P -NMR spectroscopy in the isolated rat heart Arch. Int. Pharmacodyn. Ther. 286:1987;97-110.
31. Maridonneau-Parini I., Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br. J. Clin. Pharmacol. 20:1985;148-151.
32. Maridonneau-Parini I., Garay R.P., Braquet P. The effect of lipid peroxidation on transport function in human erythrocytes. Biomed. Biochem. Acta. 42:1983;58-62.
33. Martini A., De Domenico F. Trimetazidine versus betahistine in Meniere's disease. Double blind study. Drugs Today. 26:1990;23-31. Suppl. 13.
34. Mody F.V., Singh B.N., Mohiuddin I.H., Coyle K.B., Buxton D.B., Hansen H.W., Sumida R., Schelbert H.R. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am. J. Cardiol. 82:1998;42-49.
35. Morgon A., Pech A., Labaeye P., Wayoff M., Lacomme Y., Bébéar J.P. A two-month multicenter double blind placebo controlled study of trimetazidine in tinnitus. Ann. Otolaryngol. (Paris). 107:1990;66-77.
36. Pech A. A multicenter double blind versus placebos study of trimetazidine in tinnitus. A clinical approach to tinnitus. Ann. Otolaryngol. Chir. Cervicofac. 107:1990;66-67.
37. Puel J.L. Chemical synaptic transmission in the cochlea. Prog. Neurobiol. 47:1995;449-476.
38. J.L. Puel, R. Pujol, Selective glutamate antagonists block the excitoxicity caused by either glutamate agonists or by ischemia, in: Y. Cazals, L. Demany, K.C. Horner (Eds.), Advances in Bioscience, Auditory Physiology and Perception, Pergamon, 1992, pp. 559-598.
39. Puel J.L., Gervais d'Aldin Ch., Ruel J., Ladrech S., Pujol R. Synaptic repair mechanisms responsible for functional recovery in various cochlear pathologies. Acta Otolaryngol. (Stockholm). 117:1997;214-218.
40. Puel J.L., Pujol R., Tribillac F., Ladrech S., Eybalin M. Excitatory amino acid antagonists protect cochlear auditory neurons from excitotoxicity. J. Comp. Neurol. 341:1994;241-256.
41. Puel J.L., Saffiedine S., Gervais d'Aldin Ch., Eybalin M., Pujol R. Synaptic regeneration and functional recovery after excitotoxic injury in the guinea pig cochlea. C.R. Acad. Sci. Paris, Sciences de la vie/Life Sci. 318:1995;67-75.
42. Pujol R., Eybalin M., Puel J.L. Recent advances in cohlear neurotransmission: physiology and pathophysiology. News Physiol. Sci. 10:1995;178-183.
43. Pujol R., Puel J.L., Eybalin M. Implication of non-NMDA and NMDA receptors in cochlear ischemia. NeuroReport. 3:1992;299-302.
44. Pujol R., Puel J.L., Gervais d'Aldin Ch., Eybalin M. Pathophysiology of the glutamatergic synapses in the cochlea. Acta Otolaryngol. (Stockholm). 113:1993;330-334.
45. R. Pujol, Ch. Gervais d'Aldin, S. Saffiedine, M. Eybalin, J.L. Puel, Repair of inner hair cell-auditory nerve synapses and recovery of function after an excitotoxic injury, in: R.J. Salvi, D. Henderson, F. Fiorino, V. Colletti (Eds.), Auditory System Plasticity and Regeneration, Thieme Publishers, New York, 1996, pp. 100-107.
46. Pujol R., Lenoir M., Robertson D., Eybalin M., Johnstone B.M. Kainic acid selectively alters auditory dendrites connected with cochlear inner hair cells. Hear. Res. 18:1985;145-151.
47. Pujol R., Rebillard G., Puel J.L., Eybalin M., Recasens M. Glutamate neurotoxicity in the cochlea: a possible consequence of ischemic or anoxic conditions occurring in aging. Acta Otolaryngol. (Stockholm). 476:1991;32-36.
48. 2+ regulation during cardiac cell acidosis. Cardiovasc. Drugs Ther. 1:1989;677-686.
49. Ryan A.F., Brumm D., Kraft M. Occurrence and distribution of non-NMDA glutamate receptor mRNAs in the cochlea. NeuroReport. 2:1991;643-646.
50. Safieddine S., Eybalin M. Co-expression of NMDA and AMPA/kainate receptors mRNAs in cochlear neurons. NeuroReport. 3:1992;1145-1148.
51. Safieddine S., Eybalin M. Expression of mGluR1a mRNA receptor in rat and guinea pig cochlear neurons. NeuroReport. 7:1995;193-196.
52. Salducci M.D., Chauvet-Monges A.N., Tillement J.P., Albendres E., Testa B., Carrupt P., Crevat A. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J. Pharmacol. Exp. Ther. 277:1996;417-422.
53. Schweitzer L., Jensen K.F., Janssen R. Glutamate neurotoxicity in rat auditory complex. Neurotoxicol. Teratol. 13:1991;189-193.
54. Sentex E., Sergiel J.P., Lucien A., Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol. Cell. Biochem. 175:1997;153-162.
55. Sentex E., Sergiel J.P., Lucien A., Grynberg A. Is the cytoprotective effect of trimetazidine associated with lipid metabolism? Am. J. Cardiol. 82:1998;18-24.
56. Siesjö B.K., Memezawa H., Smith M.L. Neurotoxicity: pharmacological implications. Fundam. Clin. Pharmacol. 5:1991;755-767.
57. F. Simón, P. Gil-Loyzaga, E. Hernández, F.J. Carricondo, Monosodium glutamate affects cochlear function in adult rats, 31st Workshop on Inner Ear Biology, Montpellier, France, 1994, p. 7.
58. Spoendlin H. Innervation patterns of the organ of Corti of the cat. Acta Oto-Laryngol. (Stockholm). 67:1970;239-254.
59. Tsimoyiannis E.C., Moutesidou K.M., Moschos C.M., Karayianni M., Karkabounas S., Kotoular O.B. Trimetazidine for prevention of hepatic injury induced by ischaemia and reperfusion in rats. Eur. J. Surg. 159:1993;89-93.
60. Wayoff M. Etude double insu contre placébo de l'activité de la trimétazidine dans les atteintes cochléo-vestibulaires. La Semaine des Hopitaux de Paris. 60:1984;2729.